Atyr Pharma Inc   (LIFE)
Other Ticker:  
Price: $2.9700 $0.08 2.768%
Day's High: $3.06 Week Perf: 4.95 %
Day's Low: $ 3.03 30 Day Perf: 4.58 %
Volume (M): 4 52 Wk High: $ 13.10
Volume (M$): $ 12 52 Wk Avg: $5.89
Open: $2.89 52 Wk Low: $2.60

 Market Capitalization (Millions $) 83
 Shares Outstanding (Millions) 28
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -39
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Atyr Pharma Inc

We are a global biotechnology tools company dedicated to helping our customers make scientific discoveries and ultimately improve the quality of life. Our systems, reagents, and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that better the quality of life. Life Technologies customers do their work across the biological spectrum, advancing personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. The Company employs approximately 9,700 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses.

Our systems and reagents enable, simplify and accelerate a broad spectrum of biological research of genes, proteins and cells within academic and life science research and commercial applications. Our scientific expertise assists in making biodiscovery research techniques more effective and efficient for pharmaceutical, biotechnology, agricultural, government and academic researchers with backgrounds in a wide range of scientific disciplines.

We offer many different products and services, and are continually developing and/or acquiring others. Some of our specific product categories include the following:

• “High-throughput” gene cloning and expression technology, which allows customers to clone and expression-test genes on an industrial scale.
• Pre-cast electrophoresis products, which improve the speed, reliability and convenience of separating nucleic acids and proteins.
• Antibodies, which allow researchers to capture and label proteins, visualize their location through use of Molecular Probes dyes and discern their role in disease.
• Magnetic beads, which are used in a variety of settings, such as attachment of molecular labels, nucleic acid purification, and organ and bone marrow tissue type testing.
• Molecular Probes fluorescence-based technologies, which facilitate the labeling of molecules for biological research and drug discovery.
• Transfection reagents, which are widely used to transfer genetic elements into living cells enabling the study of protein function and gene regulation.
• PCR and Real Time PCR systems and reagents, which enable researchers to amplify and detect targeted nucleic acids (DNA and RNA molecules) for a host of applications in molecular biology.
• Cell culture media and reagents used to preserve and grow mammalian cells, which are used in large scale cGMP bio-production facilities to produce large molecule biologic therapies.
• RNA Interference reagents, which enable scientists to selectively “turn off” genes in biology systems to gain insight into biological pathways.
• Capillary electrophoresis and massively parallel SOLiDtm DNA sequencing systems and reagents, which are used to discover sources of genetic and epigenetic variation, to catalog the DNA structure of organisms de novo, to verify the composition of genetic research material, and to apply these genetic analysis discoveries in markets such as forensic human identification.
• High performance mass spectrometer systems which are used in numerous applications such as drug discovery and clinical development of therapeutics as well as in basic biological research, food and beverage quality testing, environmental testing, and other applied or clinical research applications.

We divide our target customer base into three major categories:

• Life science researchers. The life sciences research market consists of laboratories generally associated with universities, medical research centers, government institutions such as the United States National Institutes of Health, or the NIH, and other research institutions as well as biotechnology, pharmaceutical, diagnostic, energy, agricultural, and chemical companies. Researchers at these institutions are using our products and services in a broad spectrum of scientific activities, such as: searching for drugs or other techniques to combat a wide variety of diseases, such as cancer and viral and bacterial disease; researching diagnostics for disease identification or for improving the efficacy of drugs to targeted patient groups; and assisting in vaccine design, bioproduction, and agriculture. Our products and services provide the research tools needed for genomics studies, proteomics studies, gene splicing, cellular analysis, and other key research applications that are required by these life science researchers.

• Commercial producers of biopharmaceutical and other high valued proteins. We serve industries that apply genetic engineering to the research and commercial production of useful but otherwise rare or difficult to obtain substances, such as proteins, interferons, interleukins, t-PA and monoclonal antibodies. Once a discovery has been proven, the manufacturers of these materials require larger quantities of the same sera and other cell growth media that we provide in smaller quantities to researchers. Industries involved in the commercial production of genetically engineered products include the biotechnology pharmaceutical, food processing and agricultural industries.

• Users who apply our technologies to enable or improve particular activities. We provide tools that apply our technology to enable or improve activities in particular markets, which we refer to as applied markets. The current focus of our products for these markets is in the areas of: forensic analysis, which is used to identify individuals based on their DNA; quality and safety testing, such as testing required to measure food, beverage, or environmental quality and pharmaceutical manufacturing quality and safety; production animal health testing, which enables the detection of pathogens in livestock; and biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers. The Applied Biosystems branded forensic testing and human identification products and services are innovative and market-leading tools that have been widely accepted by investigators and laboratories in connection with, for example, criminal investigations, the exoneration of individuals wrongly accused or convicted of crimes, identifying victims of disasters, and paternity testing.


The markets for the products of each of our segments are competitive and are characterized by the application of advanced technologies. New technologies in life sciences could make our products and services obsolete unless we continue to develop new and improved products and services and pursue new market opportunities. Given the breadth of our product and service offerings, our competition comes from a wide array of competitors with a high degree of technical proficiency, ranging from specialized companies that have strengths in narrow segments of the life science markets to larger manufacturers and distributors offering a broad array of biotechnology products and services and have significant financial, operational, research and development, and sales and marketing resources. These and other companies may have developed or could in the future develop new technologies that compete with our products or even render our products obsolete. Additionally, there are numerous scientists making materials themselves instead of using kits. We believe that a company’s competitive position in our markets is determined by product function, product quality, speed of delivery, technical support, price, breadth of product line, distribution capabilities, and timely product development. Our customers are diverse and may place varying degrees of importance on the competitive attributes listed above. While it is difficult to rank these attributes for all our customers in the aggregate, we believe we are well positioned to compete in each category.

   Company Address: 3545 John Hopkins Court San Diego 92121 CA
   Company Phone Number: 731-8389   Stock Exchange / Ticker: NASDAQ LIFE
   LIFE is expected to report next financial results on August 10, 2022.

Customers Net Income grew by LIFE's Customers Net Profit Margin grew to

57.15 %

23.81 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

Year to Date Decrease / Increase
A   -22.02%    
ABT   -21.95%    
DHR   -17%    
HON   -16.24%    
PKI   -23.91%    
TMO   -14.54%    
• View Complete Report

U.s. Lighting Group Inc.

Break-even by U.s. Lighting Group Inc in the fiscal interval ending Dec 31 2021 statement

For the fiscal interval ending Dec 31 2021 U.s. Lighting Group Inc reached break-even at $-0.00 per share, compared to results of $0.00 per share a year ago quarter, In the previous quarter company realized $0.00 per share.

Highway Holdings Limited

Income Positive Again by Highway Holdings Limited in the fiscal interval ending Mar 31 2022 statement

In the fiscal interval ending Mar 31 2022 Highway Holdings Limited earnings turn positive of $0.11 per share compared to $-0.12 a year ago and from $0.00 per share from the previous quarter.

General Mills Inc.

Solid growth at General Mills Inc in the most recent fiscal period

Sales for the most recent fiscal period increased by 8.13% to $4.89 billions in comparison to $4.52 billions on a year-over-year basis, company posted earnings growth of 99.59 % to $1.35, as comparison at $0.68 in the prior year quarter.

Gb Sciences Inc

Losses Widen, Sales are Up

For the fiscal fourth quarter of 2022 Gb Sciences Inc increased losses at $-0.01 per share, compared to results of $-0.00 per share a year ago quarter, In the previous quarter company realized $0.01 per share.

Smart Global Holdings Inc.

Income Positive Again, Single Digit Topline Growth

In the fiscal time-frame ending May 27 2022 Smart Global Holdings Inc earnings turn positive of $0.44 per share compared to $-0.30 a year ago and eps more than doubled by 1000 % from $0.04 per share from the previous quarter.



Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

TOFB's Profile

Stock Price

TOFB's Financials

Business Description


Charts & Quotes

TOFB's News


TOFB's Competitors

Customers & Markets

Economic Indicators

TOFB's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071